We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Three Lakes Foundation has recently announced that it is partnering with Lung Foundation Australia, the Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) and an Australian philanthropist with a personal connection to the rare disease.
A three-dose regimen of Plasmodium falciparum sporozoites under chemoprophylaxis (PfSPZ-CVac) was shown to be safe, well tolerated and highly effective in a Phase II trial.